Alzheimer's Disease Neuroimaging Initiative

Alzheimer's Disease Neuroimaging Initiative
Name	Alzheimer's Disease Neuroimaging Initiative
Established	2004
Focus	Alzheimer's disease, Mild cognitive impairment, Biomarker
Parent organization	National Institute on Aging

Alzheimer's Disease Neuroimaging Initiative. It is a landmark, longitudinal multicenter trial that aims to identify and validate biomarkers for the progression of Alzheimer's disease and mild cognitive impairment. Launched in 2004, it has created an extensive, publicly available repository of neuroimaging, genetic, clinical, and neuropsychological data. The initiative is widely credited with revolutionizing the clinical research framework for neurodegenerative diseases by establishing standardized methods for biomarker measurement and data sharing.

Overview

The primary goal is to develop standardized magnetic resonance imaging and positron emission tomography biomarkers for use in clinical trials and early detection. It tracks a large cohort of participants, including those with normal cognition, mild cognitive impairment, and diagnosed Alzheimer's disease, over time. The data has been instrumental in defining the biological trajectory of the disease, influencing the National Institute on Aging and Alzheimer's Association diagnostic criteria. Its collaborative model involves academic sites across North America and partnerships with the Food and Drug Administration and pharmaceutical industry.

History and funding

The project was conceived in the early 2000s by scientists and officials from the National Institute on Aging, part of the National Institutes of Health. A public-private partnership was formalized in 2004, with initial funding from the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering. Major contributions also came from the Food and Drug Administration, over twenty pharmaceutical companies including Pfizer and Eli Lilly and Company, and foundations like the Alzheimer's Association. This unique funding structure, managed through the Foundation for the National Institutes of Health, was designed to accelerate therapeutic development.

Study design and phases

The original study, known as ADNI-1, enrolled approximately 800 subjects at over 50 sites in the United States and Canada. ADNI-2, launched in 2011, expanded enrollment and added new biomarker measures. Subsequent phases, including ADNI-3, initiated further advancements in tau PET imaging and blood-based biomarkers. Each phase employs a rigorous, standardized protocol for clinical assessment, cerebrospinal fluid collection, magnetic resonance imaging, and amyloid PET scanning. The longitudinal design allows researchers to model disease progression years before clinical symptoms become apparent.

Data collection and biomarkers

Core data types include standardized 1.5 Tesla and 3 Tesla magnetic resonance imaging for measuring hippocampal volume and cortical thickness. Positron emission tomography scans utilize tracers like florbetapir and flortaucipir to quantify amyloid plaques and tau tangles. Cerebrospinal fluid is analyzed for levels of amyloid-beta and phosphorylated tau. The initiative also collects extensive genomic data, including apolipoprotein E genotype, and neuropsychological test results from the Alzheimer's Disease Assessment Scale and Mini–Mental State Examination.

Major findings and impact

Key discoveries include demonstrating that amyloid accumulation can be detected decades before dementia onset and that brain atrophy rates predict conversion from mild cognitive impairment to Alzheimer's disease. The data validated cerebrospinal fluid and PET biomarkers, leading to their incorporation into diagnostic guidelines by the National Institute on Aging. It has directly informed the design of major clinical trials conducted by organizations like the Dominantly Inherited Alzheimer Network and companies such as Biogen. The biomarker models developed are now considered the gold standard for staging the disease.

Data access and sharing

A foundational principle is the immediate public release of all data without embargo to the global scientific community. Data is accessible through the Laboratory of Neuro Imaging at the University of Southern California and the Institute for Neurodegenerative Disorders. Researchers worldwide can request access to MRI images, PET scans, clinical data, and biomarker measurements. This open-access policy has spawned thousands of secondary analyses and publications, significantly accelerating research in neurology and psychiatry beyond Alzheimer's disease.

Category:Alzheimer's disease research Category:Medical research initiatives Category:Neuroimaging